ESSA Pharma Inc. (EPIX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ESSA Pharma Inc. (EPIX). ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on developing therapies for prostate cancer. Their lead candidate, EPI-7386, is currently in Phase I clinical trials for metastatic castration-resistant prostate cancer. Sector: Healthcare.
Last analyzed: Mar 17, 2026ESSA Pharma Inc. (EPIX) Healthcare & Pipeline Overview
ESSA Pharma Inc. is a clinical-stage biotechnology firm specializing in novel therapies for prostate cancer, with its lead drug candidate, EPI-7386, undergoing Phase I clinical trials. The company operates within the competitive biotechnology sector, focusing on addressing unmet needs in metastatic castration-resistant prostate cancer treatment.
What Is the Investment Thesis for EPIX?
ESSA Pharma operates in the high-growth biotechnology sector, specifically targeting prostate cancer, a significant market with increasing prevalence. The company's lead drug candidate, EPI-7386, currently in Phase I clinical trials, represents a potential growth catalyst if it demonstrates favorable safety and efficacy data. However, the company's negative profit margin of -18611.0% and reliance on a single drug candidate present significant risks. The company's market capitalization is $0.01 billion. Successful clinical trial outcomes and strategic partnerships are crucial for driving shareholder value. The dividend yield of 840.47% should be viewed with caution, given the company's financial position. Investors should carefully consider the risks associated with clinical-stage biotechnology companies before investing.
Based on FMP financials and quantitative analysis
EPIX Key Highlights
- ESSA Pharma's lead drug candidate, EPI-7386, is currently in Phase I clinical trials for metastatic castration-resistant prostate cancer.
- The company has a market capitalization of $0.01 billion, reflecting its early-stage development and market perception.
- ESSA Pharma's profit margin is -18611.0%, indicating significant losses and reliance on external funding.
- The company's gross margin is 3.0%, highlighting the cost-intensive nature of drug development.
- ESSA Pharma has a beta of 1.53, suggesting higher volatility compared to the overall market.
Who Are EPIX's Competitors?
What Are EPIX's Key Strengths?
- Novel drug candidate targeting androgen receptor
- Strategic collaborations with established companies
- Focus on unmet need in prostate cancer treatment
- Experienced management team
What Are EPIX's Weaknesses?
- Early-stage clinical development (Phase I)
- High cash burn rate
- Reliance on a single drug candidate
- Negative profit margin
What Could Drive EPIX Stock Higher?
- Data readout from Phase I clinical trial of EPI-7386 (late 2026)
- Strategic partnerships and collaborations
- Expansion of clinical pipeline
What Are the Key Risks for EPIX?
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Funding challenges
What Are the Growth Opportunities for EPIX?
- Successful Completion of Phase I Clinical Trial: The successful completion of the Phase I clinical trial for EPI-7386 would represent a significant milestone for ESSA Pharma. Positive safety and efficacy data could attract further investment and partnership opportunities. The prostate cancer therapeutics market is projected to reach $12 billion by 2028, providing a substantial market opportunity for effective treatments. Timeline: Anticipated data readout in late 2026.
- Strategic Partnerships and Collaborations: Expanding strategic partnerships with pharmaceutical companies can provide ESSA Pharma with access to funding, expertise, and resources to accelerate drug development. Collaborations can also facilitate the expansion of the company's pipeline and market reach. The global pharmaceutical market is valued at over $1 trillion, offering ample opportunities for collaboration. Timeline: Ongoing.
- Expansion of Clinical Pipeline: Diversifying the clinical pipeline with additional drug candidates targeting different mechanisms of action in prostate cancer can reduce the risk associated with relying on a single drug. A broader pipeline can also increase the company's attractiveness to potential partners and investors. The market for novel cancer therapies is rapidly expanding. Timeline: 2027-2028.
- Breakthrough Therapy Designation: Receiving breakthrough therapy designation from regulatory agencies like the FDA could expedite the development and review process for EPI-7386. This designation is granted to drugs that demonstrate significant improvement over existing therapies for serious conditions. This could lead to faster market access and increased investor confidence. Timeline: 2027.
- Out-licensing or Acquisition: ESSA Pharma could pursue out-licensing agreements with larger pharmaceutical companies to commercialize EPI-7386 in specific geographic regions. Alternatively, the company could be acquired by a larger player seeking to expand its oncology portfolio. The pharmaceutical industry is characterized by frequent mergers and acquisitions. Timeline: 2028-2030.
What Opportunities Does EPIX Have?
- Positive clinical trial results for EPI-7386
- Expansion of clinical pipeline
- Breakthrough therapy designation
- Out-licensing or acquisition
What Threats Does EPIX Face?
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Funding challenges
What Are EPIX's Competitive Advantages?
- Proprietary drug candidate (EPI-7386)
- Intellectual property protection (patents)
- Strategic collaborations with pharmaceutical companies
- Expertise in androgen receptor biology
What Does EPIX Do?
ESSA Pharma Inc., established in 2009 and headquartered in Vancouver, Canada, is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for prostate cancer. The company's primary focus is on addressing the unmet medical needs of patients suffering from castration-resistant prostate cancer, a stage where the disease progresses despite hormonal therapies. ESSA Pharma's lead product candidate, EPI-7386, is an oral drug currently in Phase I clinical trials, evaluating its safety and efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC). EPI-7386 is designed to selectively inhibit the N-terminal domain of the androgen receptor, a key driver of prostate cancer growth. The company has established strategic collaborations with industry players such as Caris Life Sciences, Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc., to advance its research and development efforts. These collaborations provide ESSA Pharma with access to resources, expertise, and potential co-development opportunities, strengthening its position in the competitive biotechnology landscape. ESSA Pharma aims to improve outcomes for prostate cancer patients through the development of targeted therapies.
What Products and Services Does EPIX Offer?
- Develop novel therapies for prostate cancer.
- Focus on castration-resistant prostate cancer treatment.
- Advance EPI-7386, an oral drug candidate, through clinical trials.
- Collaborate with pharmaceutical companies for research and development.
- Target the androgen receptor in prostate cancer cells.
- Conduct Phase I clinical studies to evaluate safety and efficacy.
How Does EPIX Make Money?
- Develop and patent novel pharmaceutical products.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from health authorities.
- Out-license or commercialize approved products.
What Industry Does EPIX Operate In?
ESSA Pharma operates within the biotechnology industry, which is characterized by high growth potential and substantial investment in research and development. The prostate cancer therapeutics market is driven by an aging population and increasing incidence rates. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing novel therapies. ESSA Pharma's focus on selective androgen receptor inhibition positions it within a targeted therapeutic approach. The industry is subject to stringent regulatory requirements and lengthy clinical trial processes. Success depends on demonstrating clinical efficacy and safety, securing regulatory approvals, and establishing market access.
Who Are EPIX's Key Customers?
- Prostate cancer patients
- Oncologists
- Hospitals and cancer centers
EPIX Financials
EPIX Latest News
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · Sep 24, 2025
-
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
benzinga · Aug 26, 2025
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Aug 25, 2025
-
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
benzinga · Oct 16, 2023
EPIX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EPIX.
Price Targets
Wall Street price target analysis for EPIX.
EPIX MoonshotScore
What does this score mean?
The MoonshotScore rates EPIX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are EPIX's Competitors?
Latest News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Monday's After-Market Session
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Leadership: David Ross Parkinson
CEO
David Ross Parkinson brings extensive experience in oncology drug development to ESSA Pharma. He has held leadership positions at various pharmaceutical companies, overseeing clinical trials and regulatory submissions. His expertise spans preclinical research, clinical development, and commercialization. He has a strong track record of bringing innovative cancer therapies to market. His academic background includes a medical degree and specialized training in oncology.
Track Record: Under David Ross Parkinson's leadership, ESSA Pharma has advanced EPI-7386 into Phase I clinical trials. He has also secured strategic collaborations with key industry partners, strengthening the company's financial position and development capabilities. His focus on data-driven decision-making and strategic execution has been instrumental in driving the company's progress.
EPIX Healthcare Stock FAQ
What does ESSA Pharma Inc. do?
ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer. Their lead product candidate, EPI-7386, is an oral drug currently in Phase I clinical trials for metastatic castration-resistant prostate cancer. The company aims to improve outcomes for prostate cancer patients by targeting the androgen receptor, a key driver of cancer growth. ESSA Pharma collaborates with industry partners to advance its research and development efforts.
What do analysts say about EPIX stock?
Analyst coverage of ESSA Pharma Inc. (EPIX) is currently limited, reflecting its early-stage development and market capitalization. Key valuation metrics are difficult to assess due to the company's negative earnings and reliance on future clinical trial outcomes. Growth considerations are primarily focused on the successful development and commercialization of EPI-7386. Investors should conduct thorough due diligence and consider the risks associated with clinical-stage biotechnology companies.
What are the main risks for EPIX?
ESSA Pharma faces significant risks inherent in the biotechnology industry, including the potential for clinical trial failures, regulatory hurdles, and competition from established therapies. The company's reliance on a single drug candidate, EPI-7386, increases its vulnerability to adverse events. Funding challenges are also a major concern, given the company's high cash burn rate and negative profit margin. Investors should carefully evaluate these risks before investing in EPIX.
What are the key factors to evaluate for EPIX?
Evaluating EPIX involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Novel drug candidate targeting androgen receptor. Primary risk to monitor: Clinical trial failures. This is not financial advice.
How frequently does EPIX data refresh on this page?
EPIX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EPIX's recent stock price performance?
Recent price movement in ESSA Pharma Inc. (EPIX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel drug candidate targeting androgen receptor. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EPIX overvalued or undervalued right now?
Determining whether ESSA Pharma Inc. (EPIX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EPIX?
Before investing in ESSA Pharma Inc. (EPIX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.